News | March 30, 2024
Aragen operationalizes first phase of its US$ 30 million Biologics manufacturing facility in India
Executes the first project for developing and manufacturing a novel anticancer mAb
Executes the first project for developing and manufacturing a novel anticancer mAb
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Lokavant provides clinical trial intelligence
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Subscribe To Our Newsletter & Stay Updated
